Anti-Coagulants - Croatia

Croatia

In Croatia, the revenue in the Anti-Coagulants market is estimated to reach US$11.73m in 2024.
It is anticipated that there will be an annual growth rate of 7.10% (CAGR 2024-2029), leading to a market volume of US$16.53m by 2029.
When comparing globally, United States is projected to generate the highest revenue in this market, with US$16,740.00m in 2024.
The adoption of novel oral anticoagulants is steadily increasing in Croatia, providing patients with improved treatment options.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Croatia has been steadily growing in recent years, driven by several factors such as an aging population and an increase in the prevalence of cardiovascular diseases.

Customer preferences: Customers in Croatia have shown a preference for newer oral anticoagulants over traditional options such as warfarin. This is due to the convenience of not requiring regular blood tests and the decreased risk of bleeding complications. Additionally, there is a growing demand for personalized medicine, with patients seeking treatments tailored to their individual needs.

Trends in the market: One of the major trends in the Anti-Coagulants market in Croatia is the increasing use of direct oral anticoagulants (DOACs) over traditional anticoagulants. DOACs have been shown to be more effective in preventing strokes and have a lower risk of bleeding complications. Another trend is the focus on preventative care, with doctors prescribing anticoagulants to patients with a high risk of developing blood clots.

Local special circumstances: Croatia has a relatively high prevalence of cardiovascular diseases, which has contributed to the growth of the Anti-Coagulants market. Additionally, the country has an aging population, with a significant portion of the population over the age of 65. This demographic is more likely to develop conditions that require anticoagulant treatment.

Underlying macroeconomic factors: The Croatian healthcare system has undergone significant reforms in recent years, with an emphasis on increasing access to healthcare services. This has led to an increase in the number of patients seeking treatment for cardiovascular diseases and other conditions that require anticoagulants. Additionally, the country's economy has been steadily growing, which has led to increased spending on healthcare.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.